This BLYM-777 design also covers other signatures relevant for DLBCL, such as the DHITsig (n = 35) (f.e., ETV6 and RGCC) since DHIT lymphomas show an inferior survival, genes relevant in MYC driven B-cell lymphomas (n = 80) (f.e., RFC3 and TRAP1), genes upregulated in wildtype-TP53 DLBCL with high mutational burden (n = 37) (f.e., HDAC1 and BBC3), and genes relevant for the identification of resistance to CAR T-cell or bispecific antibody treatment (n = 35) (f.e., CD58 and FOXP1) [12,17,55,56,57,79,80,81,82,83,84,85,86,87,88]. The gene discussed is CD58; the disease is diffuse large B-cell lymphoma.